Susan L Slager

Dec 2, 2024 | targetedonc.com | Susan L Slager

Susan L. Slager, PhD, endowed professor of lymphoma research at Mayo Clinic, discusses some of the recommendations for genetic testing in individuals with a family history of chronic lymphocytic leukemia (CLL). While genetic testing can identify inherited variants associated with CLL risk, there are currently no preventive strategies available to mitigate these risks. In this interview, Slager highlights the importance of individualizing the decision to undergo genetic testing.

Nov 30, 2024 | targetedonc.com | Susan L Slager

Susan L. Slager, PhD, endowed professor of lymphoma research at Mayo Clinic, discusses the use of polygenic risk scoring to assess individual risk for chronic lymphocytic leukemia (CLL). According to Slager, this scoring system incorporates over 42 inherited genetic variants, each weighted based on its impact on CLL risk. By summing these weighted variants, researchers can estimate an individual's overall genetic predisposition to the disease.

Nov 26, 2024 | targetedonc.com | Susan L Slager

Susan L. Slager, PhD, endowed professor of lymphoma research at Mayo Clinic, discusses the background of her research on inherited germline genetics for risk of chronic lymphocytic leukemia (CLL). Transcription:0:09 | I am looking at the inherited germline genetics for risk of chronic lymphocytic leukemia. We and others have identified over 42 inherited variants that are associated with risk of getting CLL, and these inherited variants are distributed across the genome.

Jun 19, 2024 | nature.com | Melissa Hopper |Jordan E. Krull |C. Chris Huang |Matthew J. Maurer |Susan L Slager |Patrizia Mondello | +8 more

AbstractRecent genetic and molecular classification of DLBCL has advanced our knowledge of disease biology, yet were not designed to predict early events and guide anticipatory selection of novel therapies. To address this unmet need, we used an integrative multiomic approach to identify a signature at diagnosis that will identify DLBCL at high risk of early clinical failure. Tumor biopsies from 444 newly diagnosed DLBCL were analyzed by WES and RNAseq.

Sep 4, 2023 | nature.com | Sonja I. Berndt |Nicola J. Camp |Zhaoming Wang |Henrik Hjalgrim |Caroline Besson |Lindsay Morton | +26 more

Correction to: Leukemia https://doi.org/10.1038/s41375-022-01711-0, published online 22 October 2022In this article Arjan Diepstra at affiliation Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands was missing from the author list. The original article has been corrected. About this articleBerndt, S.I., Vijai, J., Benavente, Y. et al.